Home > Insider Trading > Filing (0001181431-11-020717)

Filing Details

Accession Number:: 0001181431-11-020717
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2011-03-30 14:10:52
Reporting Period:: 2011-03-29

Filing Date:: 2011-03-30
Accepted Time:: 2011-03-30 14:10:52
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1178711	Transcept Pharmaceuticals Inc	TSPT	Pharmaceutical Preparations (2834)	330960223

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1280249	Iii K Daniel Turner	C/O Transcept Pharmaceuticals, Inc. 1003 W. Cutting Blvd, Suite 110 Point Richmond CA 94804		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2011-03-29	65,000	$8.17	471,749	No	4	S	Indirect	See footnote
Common Stock	Disposition	2011-03-29	65,000	$8.17	569,361	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	58,178	Indirect	See footnote

Footnotes

The sale price reported in column 4 of Table I represents the weighted average sale price of the shares sold ranging from $8.10 to $8.57 per share. Upon request of the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The reported securites are owned directly by Montreux Equity Partners II SBIC, L.P. ("MEP II") and may be deemed to be beneficially owned indirectly by Montreux Equity Management II SBIC, LLC ("MEM II"), as a general partner of MEP II. The reporting person is a managing member of MEM II and disclaims any beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
The reported securites are owned directly by Montreux Equity Partners III SBIC, L.P. ("MEP III") and may be deemed to be beneficially owned indirectly by Montreux Equity Management III SBIC, LLC ("MEM III"), as a general partner of MEP III. The reporting person is a managing member of MEM III and disclaims any beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
The reported securites are owned directly by Montreux IV Associates, LLC ("Montreux IV") and may be deemed to be beneficially owned indirectly by Montreux Equity Management IV LLC ("MEM IV"), as a general partner of Montreux IV. The reporting person is a managing member of MEM IV and disclaims any beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.